Alisertib Completed Phase 1 Trials for Advanced Solid Tumors / Adenocarcinoma of the Prostate Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00962091Study of MLN8237 in Participants With Advanced Solid Tumors
NCT01094288A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen